Literature DB >> 17200926

Osmium(II) and ruthenium(II) arene maltolato complexes: rapid hydrolysis and nucleobase binding.

Anna F A Peacock1, Michael Melchart, Robert J Deeth, Abraha Habtemariam, Simon Parsons, Peter J Sadler.   

Abstract

Density functional calculations show that aquation of [Os(eta6-arene)(XY)Cl]n+ complexes is more facile for complexes in which XY=an anionic O,O-chelated ligand compared to a neutral N,N-chelated ligand, and the mechanism more dissociative in character. The O,O-chelated XY=maltolato (mal) [M(eta6-p-cym)(mal)Cl] complexes, in which p-cym=p-cymene, M=OsII (1) and RuII (2), were synthesised and the X-ray crystal structures of 1 and 22 H2O determined. Their hydrolysis rates were rapid (too fast to follow by NMR spectroscopy). The aqua adduct of the OsII complex 1 was 1.6 pKa units more acidic than that of the RuII complex 2. Dynamic NMR studies suggested that O,O-chelate ring opening occurs on a millisecond timescale in coordinating proton-donor solvents, and loss of chelated mal in aqueous solution led to the formation of the hydroxo-bridged dimers [(eta6-p-cym)M(mu-OH)3M(eta6-p-cym)]+. The proportion of this dimer in solutions of the OsII complex 1 increased with dilution and it predominated at micromolar concentrations, even in the presence of 0.1 M NaCl (conditions close to those used for cytotoxicity testing). Although 9-ethylguanine (9-EtG) binds rapidly to Os(II) in 1 and more strongly (log K=4.4) than to RuII in 2 (log K=3.9), the OsII adduct [Os(eta6-p-cym)(mal)(9EtG)]+ was unstable with respect to formation of the hydroxo-bridged dimer at micromolar concentrations. Such insights into the aqueous solution chemistry of metal-arene complexes under biologically relevant conditions will aid the rational design of organometallic anticancer agents.

Entities:  

Year:  2007        PMID: 17200926     DOI: 10.1002/chem.200601152

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  22 in total

1.  First ruthenium organometallic complex of antibacterial agent ofloxacin. Crystal structure and interactions with DNA.

Authors:  Iztok Turel; Jakob Kljun; Franc Perdih; Elena Morozova; Vladimir Bakulev; Nina Kasyanenko; Jo Ann W Byl; Neil Osheroff
Journal:  Inorg Chem       Date:  2010-10-26       Impact factor: 5.165

2.  Similar biological activities of two isostructural ruthenium and osmium complexes.

Authors:  Jasna Maksimoska; Douglas S Williams; G Ekin Atilla-Gokcumen; Keiran S M Smalley; Patrick J Carroll; Richard D Webster; Panagis Filippakopoulos; Stefan Knapp; Meenhard Herlyn; Eric Meggers
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

3.  Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.

Authors:  Maria G Mendoza-Ferri; Christian G Hartinger; Marco A Mendoza; Michael Groessl; Alexander E Egger; Rene E Eichinger; John B Mangrum; Nicholas P Farrell; Magdalena Maruszak; Patrick J Bednarski; Franz Klein; Michael A Jakupec; Alexey A Nazarov; Kay Severin; Bernhard K Keppler
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

4.  Ruthenium-nitrosyl complexes with glycine, L-alanine, L-valine, L-proline, D-proline, L-serine, L-threonine, and L-tyrosine: synthesis, X-ray diffraction structures, spectroscopic and electrochemical properties, and antiproliferative activity.

Authors:  Anna Rathgeb; Andreas Böhm; Maria S Novak; Anatolie Gavriluta; Orsolya Dömötör; Jean Bernard Tommasino; Eva A Enyedy; Sergiu Shova; Samuel Meier; Michael A Jakupec; Dominique Luneau; Vladimir B Arion
Journal:  Inorg Chem       Date:  2014-02-20       Impact factor: 5.165

Review 5.  Unusual DNA binding modes for metal anticancer complexes.

Authors:  Ana M Pizarro; Peter J Sadler
Journal:  Biochimie       Date:  2009-04-01       Impact factor: 4.079

6.  A comparative DFT study on aquation and nucleobase binding of ruthenium (II) and osmium (II) arene complexes.

Authors:  Hanlu Wang; Xingye Zeng; Rujin Zhou; Cunyuan Zhao
Journal:  J Mol Model       Date:  2013-09-15       Impact factor: 1.810

7.  Novel iridium(III) iminopyridine complexes: synthetic, catalytic, and in vitro anticancer activity studies.

Authors:  Deliang Kong; Meng Tian; Lihua Guo; Xicheng Liu; Shumiao Zhang; Yameng Song; Xin Meng; Shu Wu; Lingzi Zhang; Zhe Liu
Journal:  J Biol Inorg Chem       Date:  2018-06-11       Impact factor: 3.358

8.  Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design.

Authors:  Pieter C A Bruijnincx; Peter J Sadler
Journal:  Adv Inorg Chem       Date:  2009-07-07       Impact factor: 3.282

9.  Physicochemical Studies and Anticancer Potency of Ruthenium η-p-Cymene Complexes Containing Antibacterial Quinolones.

Authors:  Jakob Kljun; Anna K Bytzek; Wolfgang Kandioller; Caroline Bartel; Michael A Jakupec; Christian G Hartinger; Bernhard K Keppler; Iztok Turel
Journal:  Organometallics       Date:  2011-04-06       Impact factor: 3.876

10.  Osmium(ii) tethered half-sandwich complexes: pH-dependent aqueous speciation and transfer hydrogenation in cells.

Authors:  Sonia Infante-Tadeo; Vanessa Rodríguez-Fanjul; Abraha Habtemariam; Ana M Pizarro
Journal:  Chem Sci       Date:  2021-06-10       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.